Chanan-Khan, A
Egyed, M
Robak, T
Martinelli de Oliveira, F A
Echeveste, M A
Dolan, S
Desjardins, P
Blonski, J Z
Mei, J
Golany, N
Zhang, J
Gribben, J G
Article History
First Online: 31 January 2017
Competing interests
: TR—GlaxoSmithKline, Celgene Corporation: research funding; Roche, Emergent BioSolutions, Gilead Sciences, and Johnson and Johnson: advisory board and research funding. MAE—Celgene Corporation and Novartis: consultancy. JM, NG and JZ—Celgene Corporation: equity ownership and employment. JGG—Celgene Corporation, Roche, Pharmacyclics, Mundipharma and AbbVie: personal fees; Celgene Corporation: grant. The remaining authors declare no conflict of interest.